By next year, about two-thirds of American physicians will be working as salaried employees of large groups and hospitals. This movement has been underway for years. Over the last decade, the number of independent physicians was falling by about 2% a year. But these trends are now accelerating. 

The FDA should be required to disclose its reasons for rejecting a drug, and Congress should reaffirm the provisions of the FDA Modernization Act.

Many new medical technologies reduce direct health costs, but when they reduce costs in the short run, they often increase costs over the long run.

Under President Obama’s health care plan, the United States Preventive Services Task Force now wields great power to decide which health services (like mammograms) doctors should provide, yet it has few checks on its sweeping authority.

Efforts to limit the commercial use of data on physician prescribing could have broad implications for regulatory programs that promote drug safety. At issue are a series of laws pursued by state legislators that would restrict access to information on the prescriptions written by individual doctors.

This collection of essays by AEI health policy scholars distills their knowledge of health care policy and the pharmaceutical industry into key issues that need to be addressed in any reform proposal.

Requirements to test new drugs against older medicines would add a major hurdle to the development and approval of new medicines. Equally important, the proposed mandates are unnecessary.

The United States has the best cancer-survival rates in the world. Why would we import policies that would undo our progress?